Evidence map›Paper›PMID 42220011›Full record

ArticleActa oncologica (Stockholm, Sweden)2026

Oncological outcome and immune-checkpoint-blockade-induced toxicities in patients with cervical cancer - a Norwegian real-world cohort.

Katharina Bischof, Keira Matallah Fredriksen, Margrethe Bjørnstad, Mari Bunkholt Elstrand, Brynhildur Eyjolfsdottir, Alda Birgisdottir, Elisabeth Lillo, Guro Aune, Kristina Lindemann

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta oncologica (Stockholm, Sweden), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Katharina BischofDepartment of Surgical Oncology, Section for Gynaecological Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway ;Institute of Clinical Medicine, Department of Cancer Immunology, Faculty of Medicine, University of Oslo, Oslo, Norway. katbis@ous-hf.no.ORCID 0000-0001-6099-2118
Keira Matallah FredriksenDepartment of Surgical Oncology, Section for Gynaecological Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Department of Clinical and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Margrethe BjørnstadDepartment of Surgical Oncology, Section for Research and Clinical Studies, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Mari Bunkholt ElstrandDepartment of Surgical Oncology, Section for Gynaecological Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Brynhildur EyjolfsdottirDepartment of Surgical Oncology, Section for Gynaecological Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Alda BirgisdottirDepartment of Surgical Oncology, Section for Gynaecological Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Elisabeth LilloDepartment of Surgical Oncology, Section for Gynaecological Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Guro AuneDepartment of Clinical and Molecular Medicine, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim, Norway; Department of Gynaecological Oncology, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway.
Kristina LindemannDepartment of Surgical Oncology, Section for Gynaecological Oncology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Department of Surgical Oncology, Section for Research and Clinical Studies, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway; Faculty of Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeThe introduction of immune checkpoint inhibitors (ICIs) into the treatment of patients with metastatic or recurrent cervical cancer has been shown to significantly prolong survival. In this study, we examined the clinical outcomes and tolerability of treatment with ICIs in patients with metastatic or recurrent cervical cancer in a real-world setting in Norway. Patient/material and methods: This retrospective cohort study included patients treated with an ICI in combination with chemotherapy or as single agent at Oslo University Hospital between 2016 and 2024. The primary oncological endpoint was progression-free survival (PFS). Secondary endpoints include overall survival (OS) as well as tolerability.

resultsWe included 57 patients with a median age of 53 years and a median follow-up of 15.2 months. Thirty-five patients were treated with an ICI in combination with chemotherapy (cohort 1), and or an ICI alone (n = 22) (cohort 2). Forty-six patients (81%) were treated for recurrent disease. In cohort 1, the median PFS was 12.4 months (95% CI: 9.0-15.7), and the median OS was 27.5 months (95% CI: 18.0-37.1). In cohort 2, the median PFS was 3.7 months (95% CI: 2.4-5.0), and the median OS was 9.3 months (95% CI: 4.3-14.4). Nine patients (16%) discontinued treatment due to toxicity.

interpretationOur real-world data on the use of ICIs alone or in combination showed antitumour efficacy comparable to that reported in clinical studies in patients with advanced or recurrent cervical cancer. Our discontinuation rate highlights that toxicity management and mitigation are paramount when novel drugs are introduced in clinical algorithms.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsImmune Checkpoint InhibitorsNeoplasm Recurrence, LocalUterine Cervical NeoplasmsAdultAgedFemaleHumansMiddle AgedNorwayProgression-Free SurvivalRetrospective StudiesTreatment OutcomeImmune Checkpoint Inhibitors

Identifiers

PMID42220011
PMCPMC13234913

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.